2020.Oct.06

OBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA

1. Date of occurrence of the event: Oct 06, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. Reciprocal shareholding ratios: not applicable 5. Cause of occurrence: OBI filed the application to FDA of investigational device exemption (IDE) for ‘testing immunohistochemistry (IHC) of […]

HOMEWhat’s NewAnnouncementsOBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2020.Sep.28

OBI capital increases by issuance of stocks as the consideration of share exchange cooperation with Amaran Biotechnology Inc.

2020.Oct.15

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (the agreement of share exchange and cooperation signed, and trading counterparts designated)